TITLE: *Lactobacillus pentosus* KCA1 Decreases Vaginal and Gut Microbiota Associated with Bacterial Vaginosis (BV), Down-regulates IL-1 beta in Women of Child-Bearing Age and Modulates Bacterial Genes Related to Metabolic Functions.

RUNNING TITLE: *Lactobacillus pentosus* KCA1 decreases vaginal and gut-associated BV

Kingsley C Anukam^{*1,2,3} Chinwe E Ejike¹, Nneka R Agbakoba¹, Charlotte B Oguejiofor⁴.

1. Department of Medical Laboratory Sciences, Faculty of Health Sciences and Technology, College of Health Sciences, Nnamdi Azikiwe University, Nnewi Campus, NNEWI, Anambra State, Nigeria
2. Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Nnamdi Azikiwe University, Awka Campus, Anambra State, Nigeria.
3. Uzobiogene Genomics, London, Ontario, Canada
4. Department of Obstetrics and Gynaecology, Nnamdi Azikiwe University Teaching Hospital, Nnewi Campus, Anambra State, Nigeria

*CORRESPONDING AUTHOR: kc.anukam@unizik.edu.ng
ORCID: 0000-0002-2346-3345

AUTHOR CONTRIBUTIONS:

KCA, NRA and CBO designed the study, KCA sourced for funding, contributed in Definition of intellectual content; CEE and KCA did Literature search. CBO did Clinical studies; CEE performed Experimental studies. KCA acquired and analyzed data; CEE and KCA drafted the Manuscript; NRA, KCA edited and reviewed Manuscript.

ACKNOWLEDGMENT

We sincerely thank uBiome Inc, San Francisco, California, USA for awarding a grant-in-Kind to Dr. Kingsley Anukam in 2018 and for carrying out the metagenomics sequencing. We also thank Winclove Probiotics, Amsterdam, The Netherlands for Providing *Lactobacillus pentosus* KCA1 in powder form used for this study. Last but not the least, we thank all the women who participated in this study.

DISCLOSURE STATEMENT:

Dr. Kingsley C Anukam isolated, and sequenced the full genome of *Lactobacillus pentosus* KCA1, and has licensed the strain to Winclove probiotics, in The Netherlands. Winclove did not participate in the design and conduct of the study.

The protocol has been retrospectively registered online at ClinicalTrials.gov with a unique identifier: **NCT04329338**.

PRESENTATION AT A MEETING:

Part of this work was presented as a poster at the 4th Annual Conference of “Women and their Microbes” in Hamilton, Ontario, Canada. March 6-7, 2019; Organisation: **Women and their Microbes**; Place: Hamilton, Ontario, Canada.

Date: March 07, 2019

Total number of pages: 35

Total number of photographs or Figures: 13

Number of Tables = 1

Word counts

Abstract: 292

Manuscript text: 3,206

Key words: Bacterial vaginosis, probiotics, *Lactobacillus pentosus* KCA1, vagina, gut, microbiome, 16S rRNA sequencing.

ABSTRACT

Introduction: Bacterial vaginosis which affects 14-50% of reproductive-aged women in Nigeria is misdiagnosed and under-reported. Treatment option is antibiotics, which leads to recurrent infections. The objectives of this study are three folds, first to determine effects of oral feeding of *Lactobacillus pentosus* KCA1 on the vaginal and gut microbiota of women diagnosed with BV; to measure the level of two proinflammatory cytokines IL-1 beta, before and after KCA1 consumption and to determine the relative abundance of bacterial metabolic genes.

Methods: Seven women diagnosed with BV by Nugent score (7-10) were recruited to provide vaginal and gut sample before and after 14 days oral intake of 3 grams of *Lactobacillus pentosus* KCA1. The DNA from the swabs were processed for 16S rRNA metagenomics using Illumina MiSeq platform. The paired-end sequence FASTQ reads were imported into Illumina Basespace pipeline for quality check (QC). In addition, EzBioCloud pipeline was use for alpha and beta diversity estimation using PKSSU4.0 version and open reference UCLUST_MC2 for OTUs picking at 97% cut-off. Blood samples were analyzed using ELISA technique. PICRUSt was used to predict the metabolic functions from the 16S rRNA gene dataset.

Results: On average, there was no significant difference at $p=0.05$ in the alpha indices typified by Shannon index. The beta diversity showed different clustering positions with PCoA. However, at individual taxonomic categories, there was a significant decrease in the relative abundance of some genera associated with bacterial vaginosis after KCA1 feeding with a corresponding increase of *Lactobacillus* genera. Bacterial genes related to defence systems were up-regulated in the vagina. There was a 2-fold down-regulation of IL-1 beta after consumption of KCA1.

Conclusion: Our findings suggest that *Lactobacillus pentosus* KCA1 taken orally, lowers pro-inflammatory cytokine, IL-1 beta and decreases the relative abundance of BV-associated bacteria.

INTRODUCTION

Bacterial vaginosis (BV) is under-reported, misdiagnosed and inappropriately treated in Nigeria.^[1] Our recent paper reported that a large proportion of women (45.1%) assumed that vaginal discharge is the most common symptom associated with BV and 41.7% stated that BV recurrence is a common denominator in their lives. On the Social burden of BV, 53.7% of women indicated that BV makes them avoid having sex while 29.5% avoid closeness with people, yet Nigerian clinicians still rely on antibiotics.^[2] Antibiotics reduces in considerable proportion both the healthy bacteria especially Lactobacilli and those associated with BV, thus the vaginal microecology and gut is adversely affected.^[3] It is widely acknowledged that Lactobacilli and other genera that produces some metabolites such as lactic acid, contributes to vaginal health by maintaining the low pH of the vagina.^[4] Although the etiology of BV is still unresolved, a recent metagenomics study has provided an insight into the phylogenetic diversity and species richness of the vagina and gut microbiome of reproductive age women with BV in some selected Nigerian women.^[5] The polymicrobial nature of BV is also believed to induce a pro-inflammatory environment, consisting of cytokines and toll- like receptor (TLR) ligands.^[6] In Nigeria, clinicians treat BV with antibiotics combinations especially Metronidazole or Clindamycin. However, the recurrence rate remains high. Failure of the antibiotics and recurrences common in BV are attributed to various reasons such as drug resistance, failure of the agents to penetrate and eradicate biofilms formed by BV associated organisms.^[7] The concept of replenishing the vaginal microbiota can be traced back to antiquity but it was reinvigorated four decades ago by delivering lactobacilli orally to repopulate the vagina.^[8] A potential probiotic organism, *Lactobacillus pentosus* strains KCA1 was isolated for the first time from the vagina of a healthy Nigerian women. Some microbiologists have scaled up their decades of research on few vaginal Lactobacillus strains

as probiotics, thus, *Lactobacillus pentosus* KCAI was shown to produce biosurfactants, hydrogen peroxide (H₂O₂) and inhibit the intestinal and urogenital-pathogens,^[9] as well as exhibit varying degrees of acid bile tolerant.^[10]

In order to establish the genetic capability and functional potentials, the full genome sequence of *Lactobacillus pentosus* KCA1 was determined in our previous study.^[11] *Lactobacillus pentosus* KCA1 was found to dedicate 121 genes to metabolism of cofactors and vitamins including five genes for biotin biosynthesis. The *L. pentosus* KCA1 genome also encodes putative phage defense systems including CRISPRs and abortive infection, novel toxin-antitoxin systems, and biosynthesis of an antibacterial peptide, a class V cyclic bacteriocin precursor, designated as pentocin KCA1 (penA). There are five complete two-component systems in KCA1 which includes histidine kinase hpk1 (KCA1_0030) and response regulator rrp1 (KCA1_0029) and two component response regulator TrxR (KCA1_2843), a transcriptional regulator of the AraC family. There have been multiple studies showing significant improvements in treating vaginal infections with probiotics versus traditional antibiotics treatments but so far only few strains have been clinically proven to be effective in particular to prevent BV and no study has been done to determine the impact of a single *Lactobacillus* strain on the vaginal and gut microbiome. It is important to note that *Lactobacillus* strains are specific in their action according to Shanahan^[12] and Van *et al.*,^[13] denoting that one should not utilize data from one strain to infer to another untested strain that will provide the same benefit. It is critically important that *Lactobacillus pentosus* KCA1, which has been characterized at molecular level be tested clinically for probiotic use.

The genome provides a basis for its application to maintain a balanced urogenital health especially for women diagnosed with BV. The objectives of this study are three folds, first to

determine the effects before and after 14 days oral feeding of *Lactobacillus pentosus* KCA1 on the vaginal and gut microbiota compositions of women diagnosed with BV. Second to measure the level of two proinflammatory cytokines IL-1 beta and IL-6 before and after KCA1 consumption and third to determine in silico, the relative abundance of microbial genes involved in metabolic functions using the 16S rRNA dataset.

METHODS AND MATERIAL

Ethical approval: Ethical approval was obtained from the research ethics review board of the faculty of health science and technology, Nnamdi Azikiwe University (NAUTH/CS/66/10/75/2017/046) and General hospital, Onitsha, in accordance with the Helsinki Declaration of 1975, as revised in 2000 (available at http://www.wma.net/e/policy/17-c_e.html). The protocol has been registered online at ClinicalTrials.gov with a unique identifier: NCT04329338.

Study location and population

This study was conducted at General Hospital Onitsha, Anambra State. This hospital is the only government hospital at Onitsha and serves the neighbouring communities. One hundred and twenty women of reproductive age group who visited clinic at GHO were recruited for this study. The subjects were randomly selected after informed consent.

Inclusion criteria are subjects with age range 18 to 49 years, not on antibiotic therapy within the last one month and not menstruating at the time of inclusion. Subjects were **excluded if found to be** Pregnant, use of antibiotic medication, declined informed consent, menstruating and those that used douches, sprays, spermicides in the last 48 hours.

Collection of Specimen: Two high vaginal swab were collected by a qualified Gynecologist with a non-lubricated sterile disposable plastic speculum and samples were collected from the posterior vaginal fornix using a Dacron swab stick.

Microscopy and Nugent Score: Bacterial vaginosis was determined using Gram staining technique and Nugent criteria. One set of the high vaginal swab was used to prepare a dry vaginal smear which was stained by the Gram staining technique. The slides were examined using the 100x (oil immersion objective) and scored for BV using Nugent criteria. The slides were observed for presence of four different bacterial morphotypes: large Gram-positive rods (*Lactobacillus* spp. morphotypes); small Gram-variable rods (*G. vaginalis* morphotypes); small Gram-negative rods (*Bacteroides* spp. morphotypes); and curved Gram-variable rods (*Mobiluncus* spp. morphotypes). For *Lactobacillus*, scores range from 0-4; where 0 indicates that 30 or more organisms are identified and 4 indicate that no organisms are identified in the sample. For *Gardnerella* however, a score of 0 indicates that no organisms are identified and the highest score of 4 indicates that 30 or more organisms are identified. For *Mobiluncus*, scores range from 0-2 with a score of 2 indicating that 5 or more organisms are identified in the sample. At the end of scoring process, total scores ranging from 0 to 10 was computed. A total score of 7 or more was termed a case of bacterial vaginosis; a score of 4 to 6 was considered intermediate while a score of 0 to 3 was considered normal as standardized by Nugent.^[14]

Oral Administration of *Lactobacillus pentosus* KCA1

Seven women diagnosed with BV by Nugent score (7-10) were recruited to provide vaginal and gut sample before and after 14 days oral intake of 3 grams (2.5×10^8 cfu/g) of *Lactobacillus pentosus* KCA1 (Winclove probiotics, Amsterdam-The Netherlands) suspended in lukewarm

water or dairy and taken daily for 14 days. Blood samples were also collected before and after 14 days of oral consumption of *Lactobacillus pentosus* KCA1.

Extraction of bacterial DNA from vaginal swabs/stool samples and Sequencing of the amplified 16S rRNA region:

Bacterial DNA was extracted from the vaginal swabs using an in-house protocol developed by Ubiome Inc. Briefly, samples were lysed using bead-beating, and DNA was extracted in a class 1000 clean room by a guanidine thiocyanate silica column-based purification method using a liquid-handling robot. PCR amplification of the 16S rRNA genes was performed with primers containing universal primers amplifying the V4 region (515F: GTGCCAGCMGCCGCGGTAA and 806R: GGACTACHVGGGTWTCTAAT). In addition, the primers contained Illumina tags and barcodes. Samples were barcoded with a unique combination of forward and reverse indexes allowing for simultaneous processing of multiple samples. PCR products were pooled, column-purified, and size-selected through microfluidic DNA fractionation. Consolidated libraries were quantified by quantitative real-time PCR using the Kapa Bio-Rad iCycler qPCR kit on a BioRad MyiQ before loading into the sequencer. Sequencing was performed in a pair-end modality on the Illumina NextSeq 500 platform rendering 2 x 150 bp pair-end sequences.

Metagenomics sequence analysis: Raw sequence reads were demultiplexed using Illumina's BCL2FASTQ algorithm. Reads were filtered using an average Q-score > 30. The paired-end sequence FASTQ reads were imported into MG-RAST pipeline for quality check (QC). EzBiocloud Microbiome Taxonomic Profile (MTP) pipeline,^[15] was employed for alpha and beta diversity estimation using PKSSU4.0 version database and Open reference UCLUST_MC2 for OTUs picking at 97% cut-off. Sequences were pre-screened using QIIME-UCLUST algorithms

for at least 97% identity to ribosomal sequences from the RNA databases.^[16] Rarefication to 1000 reads per sample was employed to calculate microbial diversity. Alpha-diversity was calculated for species richness by ACE, Chao1 and Jackknife method, while diversity indexes were calculated by Shannon, Non-parametric Shannon and Simpson index. Principle coordinate analysis (PCoA) with Jensen-Shannon divergence distance metrics were used to evaluate beta diversity between vaginal and gut samples.^[17] Linear discriminant analysis (LDA) effect size (LEfSe)^[18] was used to identify biologically and statistically significant differences in the OTU relative abundance. Phylogenetics Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) was used to predict the metabolic function of the metagenomes from the 16S rRNA gene dataset,^[19] with reference to Kyoto Encyclopedia of Genes and Genomes (KEGG) Orthologs categorizations.^[20] Blood samples for cytokines were also collected before and after KCA1 consumption and processed with ELISA technique.

Statistical analysis: Student's T test as obtained in Excel 2019 Office was used to test differences at $p < 0.05$ in the proportion of microbiota before and after oral intake of *L. pentosus* KCA1.

RESULTS

Vaginal Microbiome composition before and after Consumption of *Lactobacillus pentosus* KCA1.

The 16S rRNA data sets comprising data before and after consumption of *Lactobacillus pentosus* KCA1 were compared by using the Greengenes Version 13_8, (ftp://greengenes.microbio.me/greengenes_release/gg_13_5/gg_13_8_otus.tar.gz) in Illumina basespace algorithm as shown in **Figure 1**. At the phyla taxonomic categories, prior to consumption of *Lactobacillus pentosus* KCA1, twenty-two phyla were identified. Firmicutes

(47.60%) were the most abundant, followed by Bacteroidetes (27.39%), Actinobacteria (17.10%), Fusobacteria (6.03%), Tenericutes (1.38%), Proteobacteria (0.44%), Acidobacteria (0.01%) and others as shown **Figure 2**. After 14 days consumption of *Lactobacillus pentosus* KCA1, twenty-two phyla were also identified with obliteration of two phyla (*Armatimonadetes* and *Planctomycetes*) and introduction of two new phyla (*Elusimicrobia* and *Nitrospirae*). Firmicutes (46.68%) were the most abundant, followed by Bacteroidetes (26.31%), Actinobacteria (18.01%), Fusobacteria (7.29%), Tenericutes (0.97%), Proteobacteria (0.66%), Acidobacteria (0.01%) and others as presented in **Figure 2**.

In addition, EzBioCloud Microbiome Taxonomic Profile (MTP) was used to determine alpha diversity including species richness and diversity index. On average, there was no significant difference ($P=0.749$) in the species richness-alpha indices typified by ACE, CHAO1, Jackknife, and number of OTUs. Diversity index such as NPS Shannon and Shannon ($P=0.749$) were not significant. Similarly, Simpson and Phylogenetic diversity ($P=0.565$) were not significant before and after KCA1 consumption (**Figure 3**). The beta diversity showed different clustering positions with Bray-Curtis Principal Coordinates Analysis (**Figure 4**). However, at individual taxonomic categories, there was a significant difference in the relative abundance of the phyla proteobacteria, actinobacteria and some genera associated with bacterial vaginosis observed before and after KCA1 feeding. For example, there was a 23.29% decrease in the genus *Gardnerella*, *Porphyromonas* (26.39%), *Prevotella* (16.1%), *Gemella* (52.07%), *Veillonella* (54.17%), *Atopobium* (43.91%), *Ureaplasma* (56.11%), and *Peptostreptococcus* decreased by 59.72%. with a corresponding 56.09% increase of *Lactobacillus* genera (**Figure 5**)

At the species taxonomic level, some bacterial organisms associated with BV decreased with higher proportions as shown in **Figure 6**. Interestingly, 113 (37%) species were exclusively

identified in the vagina of the subjects after KCA1 consumption. Notable species found after KCA1 were *Lactobacillus pentosus*, *Lactobacillus reuteri*, *Lactobacillus crispatus*, *Lactobacillus gasseri*, *Blautia wexlerae*, *Roseburia cecicola*, *Roseburia inulinivorans*, and *Faecalibacterium spp.*

Gut microbiome composition before and after Consumption of *Lactobacillus pentosus* KCA1.

The Gut microbiome before and after oral feeding of KCA1 rarefaction curve is presented in **Figure 7**. Microbiota composition at the genera taxonomic level shows that *Lactobacillus pentosus* KCA1 led to an increase in the proportion of some genera. For example, there was a 41.32% increase in *Faecalibacterium*, *Bacteroides* (29.94%), *Escherichia* (64.36%), *Clostridium* (3.93%), *Parasutterella* (3.97%), *Ruminococcus* (1.86%), *Streptococcus* (2.69%), *Lactobacillus* (3.20%), *Enterococcus* (0.22%), *Akkermansia* (0.17%) and *Butyricimonas* (0.74%). Conversely, there was a decrease in the relative abundance of some genera associated with bacterial vaginosis (**Figure 8**). *Alloprevotella* decreased by 18.05%, *Prevotella* (1.6%), *Haemophilus* (8.08%), *Intestinibacter* (2.63%), *Clostridium_g24* (0.19%), *Coprococcus* (5.13%), *Prevotellaceae_uc* (0.64%), *Fusicatenibacter* (8.33%), *Megasphaera* (0.54%), *Porphyromonas* (0.16%), *Veillonella* (0.35%), *Actinomyces* (0.02%), *Peptostreptococcus* (0.12%), *Streptococcaceae_uc* (0.15%), *Acinetobacter* (2.8%), *Anaerococcus* (0.04%), *Aeromonas* (0.17%), *Eggerthella* (0.05%), *Neisseria* (0.05%), *Campylobacter* (0.02%), *Staphylococcus* (0.02%), *Clostridium_g21* (0.08%), *Atopobium* (0.02%) and *Gardnerella* (0.09%). Some genera that were identified before oral intake of KCA1 appears to be absent after KCA1 consumption. The Venn diagram plot shows that 67.2% of the genera were commonly present before and after, while 18.7% were exclusively found after KCA1 oral intake and 14.2% were exclusively found pre-KCA1 consumption (**Figure 9**). Such genera include but not limited to *Achromobacter*, *Actinobacillus_g1*, *Actinobaculum*, *Aggregatibacter*, *Alcaligenes*, *Alishewanella*, *Anaerofustis*, *Anaerotaenia*, *Arcobacter*,

Burkholderia, *Mobiluncus*, *Pediococcus*, *Pelomonas*, *Peptococcus*, *Slackia*, *Sphingobacterium*, *Ureaplasma*, *Vallotia* and *Vibrio*. Some genera that occurred below 1% relative abundance are presented in **Figure 10**.

Metabolic Functional Prediction using the 16S rRNA Marker Genes

The results from PICRUST indicated that certain bacterial metabolic functional genes were upregulated in the vagina after consumption of *Lactobacillus pentosus* KCA1. For example, metabolic pathways for amino acid, alanine was significantly upregulated ($p = 0.008809$) with LDA effect size of 3.445098. Similarly, polar amino acid transport system substrate-binding protein with gene ortholog -K02030, was significantly increased (LDA effect size = 2.364761; and $P = 0.035006$) (**Figure 11**). There was significant difference in the predicted relative abundance of microbial gene pathways related to degradation of aromatic compounds (ko01220) with LDA effect size = 2.571179 and $P = 0.047645$. There was also high abundance of two-component system sensor histidine kinase; two-component system, OmpR family, lantibiotic biosynthesis sensor histidine kinase NisK/SpaK and redox-sensing transcriptional regulator. There were acquisitions of bacterial metabolic genes related to defence systems such as CRISPR-associated protein Cmr1, and DNA mismatch repair protein MSH3, after consumption of KCA1 in the vagina (**Table 1**)

Several bacterial metabolic functions in the gut were similarly affected. Interleukin 15 receptor alpha was downregulated significantly at $P = 0.025347$ and Methicillin resistance protein was also downregulated ($P = 0.047645$). Conversely, several microbial functional co-factors such as Menaquinone biosynthesis pathway, vitamin B6 (ko00750) metabolism, Biotin (ko00780) metabolism, Propanoate (ko00640) and Lipoic acid (ko00785) metabolisms were upregulated (**Figure 12**).

Interleukin-1 beta (IL-1 beta)

There was a 2-fold down-regulation of IL-1 beta in contrast to IL-6 after consumption of KCA1 (Figure 13)

DISCUSSIONS

In this study, we determined the composition of the vaginal and gut microbiota of women diagnosed with BV prior to and after 14 days consumption of *Lactobacillus pentosus* KCA1. In our previous study, we used metagenomics approach to decipher the composition of vaginal and gut microbiota of a small cohort of women diagnosed with BV. The study revealed the polymicrobial nature, phylogenetic diversity and species richness of the vagina and gut microbiome of reproductive age women diagnosed with BV.^[5] This present study is consistent with our previous study as the vaginal samples indicated fewer phyla in contrast to the gut. The consumption of KCA1 did not induce any significant difference in the species richness-alpha indices typified by ACE, CHAO1, Jackknife, and number of OTUs. However, at individual taxonomic categories, *L. pentosus* KCA1 led to a decrease in the proportion of bacterial organisms associated with BV with a corresponding improvement in Nugent score typified by increase in Lactobacilli. It should be noted that in healthy women, the vagina is colonized predominantly by lactobacilli as we demonstrated in our previous study whereby the vagina of healthy, non-BV Nigerian women was colonized by Lactobacillus-dominated bacterial communities, in addition to the presence of other lactic acid-producing bacteria as revealed by 16S rRNA metagenomics.^[21] In a meta-analysis review, there was a statistically significant beneficial effect of probiotics observed in European populations after short-term follow-up days.^[22] The decrease of most of the bacteria associated with BV such as *Gardnerella vaginalis* in the vagina after consumption of KCA1 and the corresponding increase of the genera *Lactobacilli* suggest that KCA1 may be

disrupting the bacterial biofilm associated with *Gardnerella vaginalis* survival.^[23,24] *Lactobacillus pentosus* KCA1 is known to produce lactic acid and genes for the production of hydrogen peroxide and bacteriocins are encoded in the genome,^[11] of which several studies have shown to affect *G. vaginalis*.^[25] A recent study demonstrated the use of *Lactobacillus* strains against two different pathogens (*Gardnerella vaginalis* and *Atopobium vaginae*) responsible for bacterial vaginosis.^[26] Restoration of vaginal microbiota after insertion of a vaginal tablet have been reported.^[27,28] The decrease of the BV associated genera (*Porphyromonas*, *Prevotella*, *Gemella*, *Veillonella*, *Atopobium*, *Ureaplasma* and *Peptostreptococcus*) suggest that *Lactobacillus pentosus* KCA1 influences multi-genera metabolic activities. For example, a study reported certain strains of *Lactobacillus* in the vagina was found to suppress the epithelial inflammatory response to *Atopobium*, linked to bacterial vaginosis.^[29] The identification of some species not found before *L. pentosus* KCA1 may indicate the possibility of cell-cross talk and quorum sensing thereby stimulating other related dormant cells to proliferate.^[30]

While *Lactobacillus pentosus* KCA1 led to decrease in BV associated organisms in the vagina, it also decreased some BV associated organisms in the gut such as *Prevotella*. Conversely, it stimulated the proliferation of some bacteria known to be associated with health. For example, There was a 41.32% increase in *Faecalibacterium* especially, *Faecalibacterium prausnitzii*, which has been found to produce high amounts of butyrate and anti-inflammatory compounds.^[31] In the same vein, *Akkermansia muciniphila* proportion was elevated. It should be noted that *Akkermansia* is involved in metabolic functions and immune regulations and have been proposed as a promising probiotic.^[32]

The *in silico* metabolic functional predictions indicated upregulation of some functions suggesting that *Lactobacillus pentosus* KCA1 impacted on the microbial activities. Intriguingly, the acquisition of microbial defense systems after consumption of KCA1 such as clustered regularly interspaced short palindromic repeats (CRISPR) is an indication that KCA1 can modulate other bacterial functions. The genome of *Lactobacillus pentosus* KCA1 encodes six CRISPR arrays with direct repeat (DR) length consensus exhibiting repeat polymorphisms. [11, 33]

The down-regulation of IL-15 by *Lactobacillus pentosus* KCA1 in the gut microbes is noteworthy, in that the cytokine correlates with adiposity and markers of the metabolic syndrome. Genome wide association (GWAS) have identified the gene encoding this receptor, IL15RA, which resides also on human chromosome 10p, a location linked to obesity and type-2 diabetes.[34] The up-regulation of Menaquinone biosynthesis pathway and vitamin B6 vitamins suggest that consumption of *Lactobacillus pentosus* KCA1 has health attributes beyond the vagina. In addition to these attributes, KCA1 has direct effect on the human host as it down-regulated serum cytokine IL-1 beta, such suggesting modulation of inflammatory processes.

CONCLUSION

Our findings suggest that *Lactobacillus pentosus* KCA1, taken orally, contributes positively to lowering pro-inflammatory cytokines, especially, IL-1 beta, with a significant decrease in the relative abundance of bacterial vaginosis-associated bacteria, and a corresponding increase of *Lactobacillus* genera. Increased metabolism of vitamin B6, biotin, lipoic acid and propanoate was observed in the gut. Bacterial genes related to defence systems were up-regulated in the vagina. The predicted metabolic functions indicate that some pathways in the vaginal microbial genes such as glycerol phosphoryl diester phosphodiesterase (K01126), mRNA

interferase MazF (K07171), two-component system sensor histidine kinase, disease resistance protein (K13446), transposase IS30 family (K07482) were significantly up-regulated after consumption of *L. pentosus* KCA1.

REFERENCES

1. Anukam KC, Osazuwa EO, Ahonkhai IN, Reid G. Association Between Absence of Vaginal Lactobacilli PCR Products and Nugent Scores Interpreted as Bacterial Vaginosis. Trop J Obstet Gynaecol, 2005; 22 (2):1-5.
2. Ejike CE, Agbakoba NR, Ezeanya CC and Anukam KC. Health, Social and Economic burden of Bacterial vaginosis (BV) among Nigerian women of child bearing age: Can Probiotics restore the vaginal dysbiosis? J Med Lab Sci, 2019; 29: 37-48
3. Anukam KC. Effects of Ampicillin on the Gut Microbiome of an Adult Male as Determined by 16S rRNA V4 Metagenomics Sequencing and Greengenes Bioinformatics Suite. Journal of Advances in Microbiology, 2017; 7(4): 1-18. DOI: 10.9734/JAMB/2017/3886.
4. Amabebe E and Anumba DOC (2018) The Vaginal Microenvironment: The Physiologic Role of *Lactobacilli*. Front. Med. 5:181. doi: 10.3389/fmed.2018.00181
5. Okoli AC, Agbakoba NR, Ezeanya CC, Oguejiofor CB, Anukam KC. Comparative Abundance and Functional Biomarkers of the Vaginal and Gut Microbiome of Nigerian Women with Bacterial Vaginosis: A Study with 16S rRNA Metagenomics. J Med Lab Sci, 2019; 29:1-26.
6. Cauci S, Guaschino S, De Aloysio D. Interrelationships of interleukin-8 with interleukin-1beta and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. Molecular Human Reproduction. 2003;9(1):53-8
7. Machado D, Castro J, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, Cerca N. Bacterial Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions. Front Microbiol. 2016, 6:1528. doi:10.3389/fmicb.2015.01528
8. Reid G, Beverman D, Heinemann C, Bruce A W. Probiotic *Lactobacillus* dose required to restore and maintain a normal vaginal floor. FEMS Immunology & Medical Microbiology, 2001; 32(1): 37 – 41.
9. Anukam, K C., Reid G. *Lactobacillus plantarum* and *Lactobacillus fermentum* with probiotic, potentials isolated from the vagina of healthy Nigeria women. J Microbiol. 2007; 2 (1): 81-87
10. Anukam KC, Koyama TE. Bile and acid tolerance of *Lactobacillus plantarum* KCA – 1: A potential probiotic agent. Int. J. Dairy Science. 2007; 2 (3): 275- 280.

11. Anukam KC, Marklaim JM, Gloor G, Reid G, Boekhorst J, Renckens B, *et al.* Genome sequence of *Lactobacillus pentosus* KCA 1: vaginal isolate from a Healthy premenopausal woman. PLOS One, 2013; 8(3): e59239. doi: 10.1371/Journal. Pone. 0059239.
12. Shanahan F. Molecular mechanism of probiotic action: it's all in strains. Gut, 2011; 60:1026 – 1027.
13. Van Barlen P, Troost F, Van der meer C. Human Mucosal *in vivo* transcriptome responses to there *Lactobacilli* indicate how probiotics may modulate human cellular pathway; Proc National Academic Science USA. 2011;108(1) 4562 – 4569
14. NugentRP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol, 1991; **29**:297-301.
15. Yoon SH, Ha SM, Kwon S, Lim J, Kim Y, Seo H, Chun J. Introducing EzBioCloud: A taxonomically united database of 16S rRNA and whole genome assemblies. Int J Syst Evol Microbiol. 2017; 67:1613-1617
16. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glockner FO. The SILVA ribosomal RNA gene database project: improved data processing and webbased tools. Nucleic Acids Res. 2013;41, Database issue: D590-D596.
17. Koren O, Knights D, Gonzalez A, Waldron L, Segata N, Knight R, *et al.* A Guide to Enterotypes across the Human Body: Meta-Analysis of Microbial Community Structures in Human Microbiome Datasets. PLoS Comput Biol 2013; 9(1): e1002863. <https://doi.org/10.1371/journal.pcbi.1002863>
Metagenomic biomarker discovery and explanation. Gen. Biol. 2011; 12.
19. Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, *et al.* Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat. Biotechnol. 2013; 31: 814–821.
20. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, knowledge and principle: Back to metabolism in KEGG. Nucleic Acids Res. 2014; 42.
21. Anukam K C, Agbakoba N R, Okoli A C, Oguejiofor C B. Vaginal bacteriome of Nigerian women in health and disease: A study with 16S rRNA metagenomics. Trop J Obstet Gynaecol 2019; 36:96-104.
22. Huang H, Song L, Zhao W. Effects of probiotics for the treatment of bacterial vaginosis in adult women: a meta-analysis of randomized clinical trials. Arch Gynecol Obstet. 2014;289 (6):1225-34. doi: 10.1007/s00404-013-3117-0.
23. Machado A, Jefferson KK, Cerca N. Interactions between *Lactobacillus crispatus* and bacterial vaginosis (BV)-associated bacterial species in initial attachment and biofilm formation. Int J Mol Sci 2013; 14:12004–12

24. Saunders S, Bocking A, Challis J, Reid G. Effect of *Lactobacillus* challenge on *Gardnerella vaginalis* biofilms. *Colloids and Surfaces B: Biointerfaces*, 2007; 55 (2):138-142
25. Patterson JL, Girerd PH, Karjane NW, Jefferson KK. Effect of biofilm phenotype on resistance of *Gardnerella vaginalis* to hydrogen peroxide and lactic acid. *Am J Obstet Gynecol* 2007; 197:170 e17
26. Bertuccini L, Russo R, Iosi F, Superti F. Effects of *Lactobacillus rhamnosus* and *Lactobacillus acidophilus* on bacterial vaginal pathogens. *Int J Immunopathol Pharmacol*. 2017 Jun;30(2):163-167. doi: 10.1177/0394632017697987.
27. Recine N1, Palma E1, Domenici L2, Giorgini M1, Imperiale L1, Sassu C1 et al. Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using *Lactobacillus rhamnosus* BMX 54 as adjuvant treatment against bacterial vaginosis. *Arch Gynecol Obstet*. 2016; 293(1):101-107. doi: 10.1007/s00404-015-3810-2.
28. Palma E, Recine N, Domenici L, Giorgini M, Pierangeli A, Panici PB. Long-term *Lactobacillus rhamnosus* BMX 54 application to restore a balanced vaginal ecosystem: a promising solution against HPV-infection. *BMC Infect Dis*. 2018;18(1):13. doi: 10.1186/s12879-017-2938-z
29. Moses RP, Hassan YD, Titilayo F, Raina NF; Onderdonk AB, Hidemi SY. *Lactobacillus* Curbs Inflammatory Responses to *Atopobium vaginae*. *Obstet Gynecol*. 2015;125, Suppl 1 3S; DOI-10.1097/01.AOG.0000463525.50901.93
30. Sturme MHJ, Francke C, Siezen RJ, de Vos WM, Kleerebezem M. Making sense of quorum sensing in *Lactobacilli*: a special focus on *Lactobacillus plantarum* WCFS1. *Microbiology* 2007;153 (12): 3939–3947.
31. Khan MT, van Dijk JM, Harmsen HJM. Antioxidants Keep the Potentially Probiotic but Highly Oxygen-Sensitive Human Gut Bacterium *Faecalibacterium prausnitzii* Alive at Ambient Air. *PLoS ONE*, 2014; 9(5): e96097. doi:10.1371/journal.pone.0096097
32. Zhang T, Li Q, Cheng L, Buch H, Zhang F. *Akkermansia muciniphila* is a promising probiotic. *Microbial Biotechnol* 2019;12(6):1109–112.
33. Anukam KC. Direct Repeats and Spacer Diversities as Found in *Lactobacillus pentosus* KCA1 CRISPR loci and Cas9 Structural Signature. *J Advances Microbiol*, 2016; 1(3): 1-13. DOI: 10.9734/JAMB/2016/31364.
34. Quinn LS, Anderson BG. Interleukin-15, IL-15 Receptor-Alpha, and Obesity: Concordance of Laboratory Animal and Human Genetic Studies. *J Obesity*, 2011 Volume 2011, Article ID 456347, 8 pages, <https://doi.org/10.1155/2011/456347>.

Table 1: Bacterial metabolic functional genes predicted with PICRUSt using EzBiocloud pipeline.

Gene Ortholog	Definition	p-value	p-value (FDR)	Vagina Before KCA1	Vagina After KCA1
K03367	D-alanine--poly(phosphoribitol) ligase subunit 1	0.002676	0.002675786	0.011612774	0.023490698
K10254	oleate hydratase	0.002676	0.002676023	0.005788293	0.019083057
K02160	acetyl-CoA carboxylase biotin carboxyl carrier protein	0.006011	0.006012273	0.008628376	0.021727122
K07469	aldehyde oxidoreductase	0.007797	0.007799211	1.69334E-06	9.58652E-05
K14007	protein transport protein SEC24	0.007797	0.007799901	1.69334E-06	4.38724E-05
K08899	lemur tyrosine kinase 3	0.009162	0.009166487	0	8.28136E-05
K05906	prenylcysteine oxidase / farnesylcysteine lyase	0.009162	0.009167297	0	3.67334E-05
K18357	phenylglyoxylate dehydrogenase gamma subunit	0.009162	0.009168108	0	6.20031E-05
K10694	E3 ubiquitin-protein ligase ZNRF1/2	0.009162	0.009168919	0	8.80003E-05
K22017	mucin-4	0.009162	0.009169729	0	0.000108002
K08353	thiosulfate reductase electron transport protein	0.009162	0.00917054	0	7.4644E-05
K13258	2-hydroxyisoflavanone dehydratase	0.009162	0.009171351	0	3.49778E-05
K16093	bacitracin synthase 1	0.009162	0.009172163	0	0.000138736
K02763	PTS system, D-glucosamine-specific IIA component	0.011593	0.011607835	1.15334E-05	0.000206032
K10049	CCAAT/enhancer binding protein (C/EBP), gamma	0.011593	0.011608862	2.88335E-06	9.26212E-05
K18841	mRNA interferase ChpB	0.011593	0.011609889	2.88335E-06	0.000106026
K18890	ATP-binding cassette, subfamily B, multidrug efflux pump	0.012716	0.012735379	0.011796924	0.028984128
K07482	transposase, IS30 family	0.012716	0.012736506	0.07559319	0.168850196
K01961	acetyl-CoA carboxylase, biotin carboxylase subunit	0.012716	0.012737634	0.012246525	0.023640415
K06501	CD68 antigen	0.016672	0.016701182	1.11901E-05	0.000221225
K07260	zinc D-Ala-D-Ala carboxypeptidase	0.018086	0.018120082	0.008296247	0.03152758
K07795	putative tricarboxylic transport membrane protein	0.018086	0.018123291	0.007612762	0.002018814
K02236	leader peptidase (prepilin peptidase) / N-methyltransferase	0.018086	0.018124895	0.00592522	0.020946159
K18592	gamma-glutamyltranspeptidase / glutathione hydrolase / leukotriene-C4 hydrolase	0.019554	0.019597171	1.69334E-06	1.812E-05
K10674	ectoine hydroxylase	0.019554	0.019598907	7.14861E-05	7.24365E-07
K14325	RNA-binding protein with serine-rich domain 1	0.023756	0.023812798	2.52825E-05	0.000102635

K16267	zinc and cadmium transporter	0.023756	0.023814907	0.00034831	2.82608E-05
K15659	arthrofactin-type cyclic lipopeptide synthetase B	0.025046	0.025110532	0	3.98252E-05
K14832	ribosome biogenesis protein MAK21	0.025046	0.025112757	0	4.61488E-05
K21368	UDP-Gal:alpha-L-Fuc-1,2-beta-Gal-1,3-alpha-GalNAc-1,3-alpha-GalNAc-diphosphoundecaprenol alpha-1,3-galactosyltransferase	0.025046	0.025114981	0	4.33456E-05
K20790	nucleoside diphosphate kinase homolog 5	0.025046	0.025117207	0	3.16051E-05
K13703	abhydrolase domain-containing protein 11	0.025046	0.025119433	0.000258153	0
K17639	ral guanine nucleotide dissociation stimulator-like 3	0.025046	0.025121659	0.000527126	0
K12526	bifunctional diaminopimelate decarboxylase / aspartate kinase	0.025046	0.025123885	0	3.16051E-05
K04334	major curlin subunit	0.025046	0.025126112	0	1.98246E-05
K14486	auxin response factor	0.025046	0.025128339	0	4.09081E-05
K06487	integrin alpha V	0.025046	0.025130567	0	4.22859E-05
K09482	glutamyl-tRNA(Gln) amidotransferase subunit D	0.025046	0.025132795	0	5.87962E-05
K20811	inulosucrase	0.025046	0.025135024	0	0.000242737
K16709	amylovoran biosynthesis protein AmsF	0.025046	0.025137252	0	1.66628E-05
K11080	mannopine transport system ATP-binding protein	0.025046	0.025139482	0	5.54126E-05
K07357	type 1 fimbriae regulatory protein FimB	0.025046	0.025141711	0	1.98246E-05
K10620	2,3-dihydroxy-2,3-dihydro-p-cumate dehydrogenase	0.025046	0.025143941	0	0.000105834
K20370	phosphoenolpyruvate carboxykinase (diphosphate)	0.025046	0.025146172	0	3.03629E-05
K10022	arginine/ornithine transport system substrate-binding protein	0.025046	0.025148403	5.19604E-05	0
K07314	serine/threonine protein phosphatase 2	0.025046	0.025150634	0	1.85825E-05
K12397	AP-3 complex subunit beta	0.025046	0.025152866	0	0.000111236
K21886	ArsR family transcriptional regulator, nickel/cobalt-responsive transcriptional repressor	0.025046	0.025155098	0	3.16051E-05
K01093	4-phytase / acid phosphatase	0.025046	0.02515733	0	1.98246E-05
K07061	CRISPR-associated protein Cmr1	0.025046	0.025159563	0	1.09144E-05
K16359	netrin-G2	0.025046	0.025161796	0	0.000147139
K09588	cytochrome P450 family 90 subfamily A polypeptide 1	0.025046	0.02516403	0	0.000175294
K13415	protein brassinosteroid insensitive 1	0.025046	0.025166264	0	0.000123999

K08736	DNA mismatch repair protein MSH3	0.025046	0.025168498	0	3.98252E-05
K10666	E3 ubiquitin-protein ligase RNF5	0.025046	0.025170733	0	0.000143705
K14837	nucleolar protein 12	0.025046	0.025172968	0	5.63805E-05
K17890	autophagy-related protein 16-1	0.025046	0.025175204	0	7.05349E-05
K18222	arylsulfatase E	0.025046	0.02517744	0	4.74866E-05
K11693	peptidoglycan pentaglycine glycine transferase (the first glycine)	0.025347	0.025482408	0.003741601	0.008570039
K01926	redox-sensing transcriptional repressor	0.025347	0.025484672	0.016331308	0.030946666
K03740	D-alanine transfer protein	0.025347	0.025486936	0.013102146	0.027267324
K11616	malate:Na ⁺ symporter	0.025347	0.025489201	0.003303801	0.011965665
K07467	phage replication initiation protein	0.025347	0.025491466	0.004323412	0.016619946
K03355	anaphase-promoting complex subunit 8	0.025347	0.025493731	0.000753232	0.000311673
K01126	glycerophosphoryl diester phosphodiesterase	0.025347	0.025495997	0.026346323	0.048183715
K01728	pectate lyase	0.025347	0.025498263	0.004898644	0.013124259
K07487	transposase	0.025347	0.025500529	0.018114649	0.258579872
K10047	inositol-phosphate phosphatase / L-galactose 1-phosphate phosphatase	0.028286	0.028459509	5.7667E-06	0.000119604
K21801	indoleacetamide hydrolase	0.028286	0.028462039	0.000305014	1.44873E-06
K10624	E3 ubiquitin-protein ligase RBBP6	0.033347	0.033557197	1.32366E-05	0.000178172
K20098	DNA excision repair protein ERCC-6-like 2	0.033347	0.033560181	7.43275E-06	0.000118784
K03357	anaphase-promoting complex subunit 10	0.033347	0.033563165	1.82381E-05	0.000217177
K21672	2,4-diaminopentanoate dehydrogenase	0.033347	0.03356615	2.3718E-05	0.000151075
K02852	UDP-N-acetyl-D-mannosaminouronate:lipid I N-acetyl-D-mannosaminouronosyltransferase	0.034435	0.034664834	2.07059E-05	4.80906E-05
K06019	pyrophosphatase PpaX	0.035006	0.035242333	0.001494945	0.009196995
K03695	ATP-dependent Clp protease ATP-binding subunit ClpB	0.035006	0.035245468	0.100888013	0.079081389
K00712	poly(glycerol-phosphate) alpha-glucosyltransferase	0.035006	0.035248604	0.007927823	0.020564455
K22305	phosphoserine phosphatase	0.035006	0.03525174	0.0027264	0.013205239
K02049	NitT/TauT family transport system ATP-binding protein	0.035006	0.035254877	0.089892498	0.112688192
K00887	undecaprenol kinase	0.035006	0.035258015	0.009129932	0.022865891
K01198	xylan 1,4-beta-xylosidase	0.035006	0.035261153	0.005169175	0.010305476

K07483	transposase	0.035006	0.035264291	0.091623295	0.250486331
K07171	mRNA interferase MazF	0.035006	0.03526743	0.010735722	0.024242624
K01607	4-carboxymuconolactone decarboxylase	0.035006	0.03527057	0.03435543	0.049065032
K07717	two-component system, sensor histidine kinase YcbA	0.035006	0.03527371	0.001835765	0.010390348
K17462	putative AdoMet-dependent methyltransferase	0.035006	0.035276851	0.003619675	0.007277721
K02030	polar amino acid transport system substrate-binding protein	0.035006	0.035279992	0.1493949	0.195517253
K16342	cytosolic phospholipase A2	0.04019	0.040508252	2.04489E-05	0.000114601
K15044	Arf-GAP domain and FG repeats-containing protein 1	0.04019	0.04051186	2.88335E-06	3.81121E-05
K19673	tetratricopeptide repeat protein 21B	0.04019	0.040515469	3.38667E-06	0.000106309
K10820	monosaccharide-transporting ATPase	0.04019	0.040519078	4.51824E-06	8.73693E-05
K22395	cinnamyl-alcohol dehydrogenase	0.04019	0.040522687	4.88522E-05	7.46067E-06
K20324	mutacin VI	0.042812	0.043171024	1.85117E-05	9.70858E-05
K08052	neurofibromin 1	0.042812	0.04317487	0.000550575	1.57543E-05
K21140	[CysO sulfur-carrier protein]-S-L-cysteine hydrolase	0.04667	0.04706947	2.88844E-05	0.000274593
K05291	phosphatidylinositol glycan, class S	0.04667	0.047073665	2.5701E-05	0.0003826
K08312	ADP-ribose diphosphatase	0.04667	0.04707786	5.14749E-05	0.000140524
K13446	disease resistance protein	0.04667	0.047082057	2.5701E-05	0.000109775
K00073	ureidoglycolate dehydrogenase (NAD+)	0.04667	0.047086254	0.000114001	0.000436769
K15331	tRNA (uracil-5-)-methyltransferase	0.047401	0.047828057	5.10439E-05	0.000160251
K00889	1-phosphatidylinositol-4-phosphate 5-kinase	0.047645	0.04807872	0.001242012	0.009247603
K07149	uncharacterized protein	0.047645	0.048083007	0.004262954	0.008282736
K14731	epsilon-lactone hydrolase	0.047645	0.048087295	0.007734517	0.02568202
K20608	tetrahedral aminopeptidase	0.047645	0.048091584	0.000710356	0.000166675
K14188	D-alanine--poly(phosphoribitol) ligase subunit 2	0.047645	0.048095873	0.008249537	0.019178857
K20487	two-component system, OmpR family, lantibiotic biosynthesis sensor histidine kinase NisK/SpaK	0.047645	0.048100163	0.006111161	0.021792519
K00042	2-hydroxy-3-oxopropionate reductase	0.047645	0.048104454	0.002712254	0.006392267
K00637	sterol O-acyltransferase	0.047645	0.048108745	0.000749673	0.000398902

Figures and Figure Legends

Figure 1: Distribution of total taxonomic categories in BV subjects before and after KCA1 consumption

Distribution of Phyla taxonomic categories in BV subjects before and after KCA1 consumption

Figure 2: Distribution of Phyla taxonomic categories identified in BV subjects before and after *L pentosus* KCA1 consumption

Figure 3: Alpha diversity index showing the species richness as determined by EzBioCloud MTP pipeline

Figure 4: **Beta diversity** showing different clustering positions before and after *L pentosus* KCA1 with Bray-Curtis Principal Coordinates Analysis

Figure 5: Vaginal bacteriome genera compositions before and after oral consumption of *Lactobacillus pentosus* KCA1

Figure 6: **Selected vaginal bacteriome species before and after oral consumption of *Lactobacillus pentosus* KCA1.**

Figure 7: Rarefaction curve showing the number of reads from gut samples associated with the number of operational taxonomic units (OTUs)

Figure 8: Gut relative abundance genera (above 1%) before and after consumption of *Lactobacillus pentosus* KCA1

Figure 9: Venn diagram showing the number (%) of genus and species identified in the gut that were common and exclusive before and after oral intake of *L. pentosus* KCA1

Figure 10: Gut relative abundance genera (below 1% cutoff) before and after consumption of *Lactobacillus pentosus* KCA1.

Figure 11: Bacterial metabolic functional genes upregulated in the vagina after oral intake of *L. pentosus* KCA1

Figure 12: Bacterial metabolic functional genes upregulated in the gut after oral intake of *L. pentosus* KCA1.

Figure 13: Showing box plot of the serum IL-1 beta and IL-6 before and after 14 days oral intake of *L. pentosus* KCA1.